FI946066A0 - Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina - Google Patents

Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina

Info

Publication number
FI946066A0
FI946066A0 FI946066A FI946066A FI946066A0 FI 946066 A0 FI946066 A0 FI 946066A0 FI 946066 A FI946066 A FI 946066A FI 946066 A FI946066 A FI 946066A FI 946066 A0 FI946066 A0 FI 946066A0
Authority
FI
Finland
Prior art keywords
hepatitis
therapeutic
diagnostic agents
new sequences
present
Prior art date
Application number
FI946066A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI946066A (fi
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of FI946066A publication Critical patent/FI946066A/fi
Publication of FI946066A0 publication Critical patent/FI946066A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI946066A 1993-04-27 1994-12-23 Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina FI946066A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93401099 1993-04-27
EP93402019 1993-08-05
PCT/EP1994/001323 WO1994025601A2 (en) 1993-04-27 1994-04-27 New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
FI946066A FI946066A (fi) 1994-12-23
FI946066A0 true FI946066A0 (fi) 1994-12-23

Family

ID=26134679

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946066A FI946066A0 (fi) 1993-04-27 1994-12-23 Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina

Country Status (15)

Country Link
US (3) US7157226B1 (de)
EP (4) EP0984068B1 (de)
JP (5) JPH07508423A (de)
CN (1) CN1108030A (de)
AT (4) ATE552340T1 (de)
AU (1) AU688323B2 (de)
BR (1) BR9405334A (de)
CA (2) CA2662090A1 (de)
DE (1) DE69435023T2 (de)
ES (1) ES2294779T3 (de)
FI (1) FI946066A0 (de)
NO (1) NO944967L (de)
NZ (1) NZ266148A (de)
SG (1) SG50563A1 (de)
WO (1) WO1994025601A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763159A (en) 1991-11-21 1998-06-09 Common Services Agency Hepatitis-C virus testing
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US7258977B1 (en) * 1992-11-27 2007-08-21 Innogenetics N.V. Process for typing of HCV isolates
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
CA2662090A1 (en) 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
DE69434116T2 (de) 1993-05-05 2005-10-27 Common Services Agency Hepatitis-c virus typ 4,5 und 6
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
JPH10507643A (ja) * 1994-10-21 1998-07-28 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
WO1998012332A1 (en) * 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
WO1999054735A1 (en) 1998-04-17 1999-10-28 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
DE19980730D2 (de) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunpharmaka zur Therapie der Hepatitis C
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
DE69934810T2 (de) * 1998-06-09 2007-10-11 Branch, Andrea D. Neues hepatitis c viruspeptid und seine verwendung
BRPI0111731C1 (pt) 2000-06-15 2021-07-27 Chiron Corp suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico
AU2001290178A1 (en) * 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7196183B2 (en) * 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
MD2149G2 (ro) * 2001-11-23 2003-10-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
DE60332781D1 (de) 2002-03-11 2010-07-08 Lab 21 Ltd Verfahren und Zusammensetzungen zur Identifizierung und Charakterisierung von Hepatitis C
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2345420B1 (de) 2003-03-24 2016-01-06 Valneva Austria GmbH Verwendung eines TH1-Immunantwort induzierenden Adjuvans zur Erhöhung der Immunantworten
DE602004030343D1 (de) 2003-07-11 2011-01-13 Intercell Ag Hcv-vakzin
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2005067643A2 (en) * 2004-01-07 2005-07-28 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
US20060162667A1 (en) * 2005-01-26 2006-07-27 Papadoyianis Ernest D Aquatic habitat and ecological tank
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
MD3300G2 (ro) * 2006-09-28 2007-11-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
EP2121990A2 (de) * 2006-10-20 2009-11-25 Innogenetics N.V. Methodik zur analyse von sequenzvariationen innerhalb des hcv-ns5b-genombereichs
EP2463390A1 (de) 2006-10-20 2012-06-13 Innogenetics N.V. Methodik zur Analyse von Sequenzvariationen innerhalb des HCV-NS5B-Genombereichs
EP2121991A2 (de) 2006-10-20 2009-11-25 Innogenetics N.V. Methodik zur analyse von sequenzvariationen innerhalb des hcv-ns3/4a-genombereichs
EA018102B1 (ru) * 2007-08-09 2013-05-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ идентификации генотипа и подтипа вируса гепатита c на биологическом микрочипе
EP2185195A2 (de) * 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
BRPI0818488A2 (pt) * 2007-10-30 2015-04-14 Intermune Inc Genotipagem e fenotipagem de hcv
CN102378914B (zh) * 2009-03-30 2014-12-10 生物梅里埃公司 用于hcv检测的固体支持物
WO2013150450A1 (en) * 2012-04-02 2013-10-10 Universidade Do Porto Hcv homolog fragments, cell-lines and applications thereof
ES2832335T3 (es) * 2015-03-27 2021-06-10 Ortho Clinical Diagnostics Inc Polipéptidos NS4A/NS3 modificado del VHC y usos de los mismos
CN109642253A (zh) * 2016-08-02 2019-04-16 豪夫迈·罗氏有限公司 用于提高核酸的扩增和检测/定量的效率的辅助寡核苷酸

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
ES2012739T5 (es) * 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
GB2236819B (en) * 1989-09-14 1993-07-14 Gen Motors France Dual master cylinder
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
JP3156200B2 (ja) 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
NL9002779A (nl) 1989-12-18 1991-07-16 Wellcome Found Viraal middel.
EP0435229A1 (de) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNS-Gen von einem Non-A Non-B Hepatitis-Virus, seine Klonierung und Verwendung
WO1991014779A1 (en) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic for hepatitis virus
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
ES2138784T3 (es) 1990-12-14 2000-01-16 Innogenetics Nv Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
EP0510952A1 (de) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonukleotid-Primer und ihre Anwendung zum Nachweis von Non-A, Non-B-Hepatitis mit höchster Genauigkeit
ATE252154T1 (de) * 1991-05-08 2003-11-15 Chiron Corp Genomische hcv-sequenzen für diagnostik und therapie
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
EP0532167A3 (en) * 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
CA2115926A1 (en) * 1991-08-21 1993-03-04 Stephen H. Dailey Hepatitis c assay utilizing recombinant antigens to ns1
RU2212899C2 (ru) * 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
US5763159A (en) * 1991-11-21 1998-06-09 Common Services Agency Hepatitis-C virus testing
SG46456A1 (en) * 1992-11-27 1998-02-20 Innogenetics Nv Process for typing of hcv isolates
CA2662090A1 (en) 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
ATE281647T1 (de) 1993-05-10 2004-11-15 Chiron Corp Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
JPH06319563A (ja) 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5882852A (en) 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JP2687852B2 (ja) * 1993-10-13 1997-12-08 日本電気株式会社 半導体メモリ装置

Also Published As

Publication number Publication date
US7157226B1 (en) 2007-01-02
JP2004041206A (ja) 2004-02-12
JP2002233388A (ja) 2002-08-20
AU688323B2 (en) 1998-03-12
NZ266148A (en) 1997-06-24
ATE553201T1 (de) 2012-04-15
US20030008274A1 (en) 2003-01-09
ATE552340T1 (de) 2012-04-15
EP1004670A3 (de) 2000-09-20
JPH07508423A (ja) 1995-09-21
US7195765B2 (en) 2007-03-27
CN1108030A (zh) 1995-09-06
DE69435023D1 (de) 2007-10-25
AU6722294A (en) 1994-11-21
EP1004670B1 (de) 2012-04-11
NO944967D0 (no) 1994-12-21
WO1994025601A3 (en) 1995-03-02
CA2139100A1 (en) 1994-11-10
DE69435023T2 (de) 2008-09-11
BR9405334A (pt) 1999-05-25
ATE551423T1 (de) 2012-04-15
EP1004670A2 (de) 2000-05-31
EP0984068B1 (de) 2012-03-28
NO944967L (no) 1994-12-21
CA2139100C (en) 2009-06-23
FI946066A (fi) 1994-12-23
JP2002233389A (ja) 2002-08-20
SG50563A1 (en) 1998-07-20
EP0651807B1 (de) 2007-09-12
US6762024B2 (en) 2004-07-13
WO1994025601A2 (en) 1994-11-10
EP0984068A3 (de) 2000-09-20
JP2004041207A (ja) 2004-02-12
EP0984067A2 (de) 2000-03-08
ATE373093T1 (de) 2007-09-15
ES2294779T3 (es) 2008-04-01
EP0651807A1 (de) 1995-05-10
EP0984068A2 (de) 2000-03-08
US20030032005A1 (en) 2003-02-13
CA2662090A1 (en) 1994-11-10
EP0984067B1 (de) 2012-04-04
EP0984067A3 (de) 2000-09-27

Similar Documents

Publication Publication Date Title
FI946066A0 (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
CA2108466A1 (en) Hcv genomic sequences for diagnostics and therapeutics
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
RU96119350A (ru) Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу)
SE9004010D0 (sv) Viralt medel
DK0770679T4 (da) HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
ES2175462T3 (es) Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
ATE150086T1 (de) Cdns-sequenz und detektion des hepatitis c-virus
Yoshioka et al. Deficiency of antibody response to hypervariable region of hepatitis C virus in patients with chronic hepatitis C
TH7280A (th) เพปไทด์ที่เป็นแอนติเจนของไวรัสโรคตับอักเสบชนิดnon-A,non-B
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열